Strategies used for MUC1 immunotherapy: Human clinical studies

Expert Review of Vaccines

Volumn 7, Issue 7, 2008, Pages 963-975

  Tang, Choon Kit ^a   Katsara, Maria ^a   Apostolopoulos, Vasso ^a  

^a BURNET INSTITUTE   (Australia)

Author keywords

Antigen delivery; Cancer; Clinical trial; Human study; Immunotherapy; MUC1; Mucin; Vaccine

Indexed keywords

BCG VACCINE; BLP 25; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD164 ANTIGEN; CD34 ANTIBODY; CELL ADHESION MOLECULE; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXOID; GLUTATHIONE TRANSFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LEUKOSIALIN; MANNAN; METRONIDAZOLE; MUCIN 1; MUCIN VNTR PEPTIDE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PLACEBO; QS 21; SIALOMUCIN; TAMOXIFEN; TG 1031; TG 4010; TG 5058; THERATOPE; TRICOM VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; GENE OVEREXPRESSION; HELPER CELL; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGENICITY; MOLECULAR WEIGHT; PRIORITY JOURNAL; REVIEW; VARIABLE NUMBER OF TANDEM REPEAT;

CA-15-3 ANTIGEN; CANCER VACCINES; HUMANS; NEOPLASMS;

EID: 51349116036     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.7.963     Document Type: Review

References (109)

1. Apostolopoulos V, Hu XF, Pouniotis DS, Xing PX. MUC1: a molecule of many talents. Curr. Trends Immunol. 12, 629-639 (2004).
2. Apostolopoulos V, McKenzie IF, Pietersz GA. Breast cancer immunotherapy: current status and future prospects. Immunol. Cell Biol. 74(5), 457-464 (1996).
3. Apostolopoulos V, Pietersz GA, McKenzie IF. MUC1 and breast cancer. Curr. Opin. Mol. Ther. 1(1), 98-103 (1999).
4. McKenzie IF, Apostolopoulos V, Plebanski M, Pietersz GA, Loveland BE. Aspects of cancer immunotherapy. Immunol. Cell Biol. 81(1), 79-85 (2003).
5. Itoh Y, Kamata-Sakurai M, Denda-Nagai K et al. Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucin. Glycobiology 18(1), 74-83 (2008).
6. McGuckin MA. CD227 (MUC1) - summary and workshop report. In: Leucocyte Typing VII. Mason D (Ed.). Oxford University Press, Oxford, UK, 54-56 (2001).
7. Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res. 68(7), 2419-2426 (2008).
8. Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev. Vaccines 4(4), 493-502 (2005).
9. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 82, 249-293 (2004).
10. Tang C-K, Apostolopoulos V. Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev. Vaccines 7(7), 951-962 (2008).
11. Apostolopoulos V, Pietersz GA, McKenzie IF. Studies of MUC1 peptides. In: Peptide Based Cancer Vaccines. Medical Intelligence Unit Series. Kast MW (Ed.). Landes Bioscience, Chapman and Hall, London, UK 106-120 (2000).
12. Xing PX, Michael M, Apostolopoulos V et al. Phase I study of synthetic MUC1 peptides in breast cancer. Int. J. Oncol. 6, 1283-1289 (1995). • First paper demonstrating that MUC1 peptides in humans are safe and induce immune responses.
13. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63(1), 298-304 (1996).
14. Reddish M, MacLean GD, Koganty RR et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int. J. Cancer 76(6), 817-823 (1998).
15. Karanikas V, Hwang LA, Pearson J et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100(11), 2783-2792 (1997).
16. van Leeuwen EB, Cloosen S, Senden-Gijsbers BL et al. Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector. Cytotherapy 8(1), 24-35 (2006).
17. van Leeuwen EB, Cloosen S, Senden-Gijsbers BL, Germeraad WT, Bos GM. Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC. Cytotherapy 8(1), 36-46 (2006).
18. Trevor KT, Hersh EM, Brailey J, Balloul JM, Acres B. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol. Immunother. 50(8), 397-407 (2001).
19. Maruyama K, Akiyama Y, Nara-Ashizawa N et al. Adenovirus-mediated MUC1 gene transduction into human blood-derived dendritic cells. J. Immunother. 24(4), 345-353 (2001).
20. Pecher G, Spahn G, Schirrmann T et al. Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus. Anticancer Res. 21(4A), 2591-2596 (2001).
21. Koido S, Hara E, Homma S et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 11(21), 7891-7900 (2005).
22. Koido S, Hara E, Homma S et al. Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J. Immunol. 179(7), 4874-4883 (2007).
23. Napoletano C, Rughetti A, Agervig Tarp MP et al. Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res. 67(17), 8358-8367 (2007).
24. Apostolopoulos V. Methods of delivery to antigen-presenting cells: development of new and improved vaccines. Mol. Pharm. 4(1), 1-3 (2007).
25. Pietersz GA, Pouniotis DS, Apostolopoulos V. Design of peptide-based vaccines for cancer. Curr. Med. Chem. 13(14), 1591-1607 (2006).
26. Proudfoot O, Apostolopoulos V, Pietersz GA. Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol. Pharm. 4(1), 58-72 (2007).
27. Tang C-K, Sheng K-C, Apostolopoulos V, Pietersz GA. Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors. Expert Rev. Vaccines 7(7), 1005-1018 (2008).
28. Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 18(27), 3174-3184 (2000).
29. Apostolopoulos V, McKenzie IF. Role of the mannose receptor in the immune response. Curr. Mol. Med. 1(4), 469-474 (2001).
30. Apostolopoulos V, Haurum JS, McKenzie IF. MUC1 peptide epitopes associated with five different H-2 class I molecules. Eur. J. Immunol. 27(10), 2579-2587 (1997).
31. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 159(11), 5211-5218 (1997).
32. Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IF. CTL in mice immunized with human mucin 1 are MHC-restricted. J. Immunol. 155(11), 5089-5094 (1995).
33. Apostolopoulos V, McKenzie IF, Lees C, Matthaei KI, Young IG. A role for IL-5 in the induction of cytotoxic T lymphocytes in vivo. Eur. J. Immunol. 30(6), 1733-1739 (2000).
34. Apostolopoulos V, McKenzie IF, Pietersz GA. Generation of MUC1 cytotoxic T-cells in mice and epitope mapping. Methods Mol. Biol. 125, 455-462 (2000).
35. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl Acad. Sci. USA 92(22), 10128-10132 (1995).
36. Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14(9), 930-938 (1996).
37. Apostolopoulos V, Popovski V, McKenzie IF. Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP). J. Immunother. 21(2), 109-113 (1998).
38. Apostolopoulos V, Yu M, Corper AL et al. Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J. Mol. Biol. 318(5), 1293-1305 (2002).
39. Lees CJ, Apostolopoulos V, Acres B, Ong CS, Popovski V, McKenzie IF. The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan-MUC1. Cancer Immunol. Immunother. 48(11), 644-652 (2000).
40. Lees CJ, Apostolopoulos V, Acres B et al. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine 19(2-3), 158-162 (2000).
41. Lees CJ, Apostolopoulos V, McKenzie IF. Cytokine production from murine CD4 and CD8 cells after mannan-MUC1 immunization. J. Interferon Cytokine Res. 19(12), 1373-1379 (1999).
42. Lofthouse SA, Apostolopoulos V, Pietersz GA, Li W, McKenzie IF. Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen. Vaccine 15(14), 1586-1593 (1997).
43. McKenzie IF, Apostolopoulos V, Lees C et al. Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses. Vet. Immunol. Immunopathol. 63(1-2), 185-190 (1998).
44. Pietersz GA, Li W, Popovski V, Caruana JA, Apostolopoulos V, McKenzie IF. Parameters for using mannan-MUC1 fusion protein to induce cellular immunity. Cancer Immunol. Immunother. 45(6), 321-326 (1998).
45. Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur. J. Immunol. 30(6), 1714-1723 (2000).
46. Apostolopoulos V, Yuriev E, Ramsland PA et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc. Natl Acad. Sci. USA 100(25), 15029-15034 (2003).
47. Karanikas V, Lodding J, Maino VC, McKenzie IF. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin. Cancer Res. 6(3), 829-837 (2000).
48. Karanikas V, Thynne G, Mitchell P et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J. Immunother. 24(2), 172-183 (2001).
49. Apostolopoulos V, Pietersz GA, Tsibanis A et al. Pilot Phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 8(3), R27 (2006). •• Pilot Phase III study demonstrating that in early breast cancer patients with no evidence of disease, MUC1 immunotherapy is beneficial. Patients injected with MUC1 vaccine are protected against recurrence compared with placebo-controlled cohorts.
50. Apostolopoulos V, Matsoukas J, Plebanski M, Mavromoustakos T. Applications of peptide mimetics in cancer. Curr. Med. Chem. 9(4), 411-420 (2002).
51. Apostolopoulos V, Lofthouse SA, Popovski V, Chelvanayagam G, Sandrin MS, McKenzie IF. Peptide mimics of a tumor antigen induce functional cytotoxic T cells. Nat. Biotechnol. 16(3), 276-280 (1998).
52. Apostolopoulos V, Osinski C, McKenzie IF. MUC1 cross-reactive Gal a(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat. Med. 4(3), 315-320 (1998).
53. Apostolopoulos V, Sandrin MS, McKenzie IF. Mimics and cross reactions of relevance to tumour immunotherapy. Vaccine 18(3-4), 268-275 (1999).
54. Apostolopoulos V, Sandrin MS, McKenzie IF. Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy. J. Mol. Med. 77(5), 427-436 (1999).
55. Loveland BE, Zhao A, White S et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 12(3 Pt 1), 869-877 (2006). •• Ex vivo-cultured monocyte derived dendritic cells (moDCs) pulsed with mannan-MUC1 induce strong cellular responses in advanced adenocarcinoma patients.
56. Brossart P. Dendritic cells in vaccination therapies of malignant diseases. Transfus. Apher. Sci. 27(2), 183-186 (2002).
57. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96(9), 3102-3108 (2000). • Ex vivo-grown moDCs pulsed with MUC1 peptide induce immune responses in patients with cancer.
58. Wierecky J, Mueller M, Brossart P. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol. Immunother. 55(1), 63-67 (2006).
59. Wierecky J, Muller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66(11), 5910-5918 (2006). • Immunization of patients with ex vivo-cultured DCs pulsed with MUC1 peptides and re-injected into advanced renal cell carcinoma patients offers immune responses in patients.
60. Kontani K, Taguchi O, Ozaki Y et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int. J. Mol. Med. 12(4), 493-502 (2003).
61. Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol. Immunother. 51(11-12), 669-673 (2002). • MUC1 cDNA-transfected DCs injected into patients induce immune responses.
62. Sheng KC, Pietersz GA, Wright MD, Apostolopoulos V. Dendritic cells: activation and maturation - applications for cancer immunotherapy. Curr. Med. Chem. 12(15), 1783-1800 (2005).
63. Kondo H, Hazama S, Kawaoka T et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res. 28(1B), 379-387 (2008). •• First demonstration that injection of both MUC1 DCs and MUC1 cytotoxic T-lymphocytes in advanced pancreatic cancer patients induces immune and clinical responses in patients.
64. Gong J, Koido S, Calderwood SK. Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev. Vaccines 7(7), 1055-1068 (2008).
65. Avigan D. Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin. Cancer Res. 10(18 Pt 2), 6347S-6352S (2004). •• DC-tumor fusion vaccine in patients with kidney cancer induces immune responses.
66. Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10(14), 4699-4708 (2004).
67. Chang GC, Lan HC, Juang SH et al. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer 103(4), 763-771 (2005).
68. Gilewski T, Adluri S, Ragupathi G et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6(5), 1693-1701 (2000). • Use of MUC1 variable number tandem repeats peptide-keyhole limpet hemocyanin (KLH) mixed with QS21 as a vaccine.
69. Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y, Livingston PO. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int. J. Cancer 97(5), 660-667 (2002).
70. Ramanathan RK, Lee KM, McKolanis J et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 54(3), 254-264 (2005).
71. Yamamoto K, Ueno T, Kawaoka T et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res. 25(5), 3575-3579 (2005).
72. Palmer M, Parker J, Modi S et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clinical Lung Cancer 3(1), 49-57 (2001).
73. Butts C, Murray N, Maksymiuk A et al. Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27), 6674-6681 (2005). • Results of L-BLP-25 vaccine in advanced non-small-cell lung cancer patients.
74. North SA, Graham K, Bodnar D, Venner P. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J. Urol. 176(1), 91-95 (2006). • Results of L-BLP-25 vaccine in advanced prostate cancer patients.
75. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin. Cancer Res. 13(15 Pt 2), S4652-S4654 (2007).
76. Sangha R, North S. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opin. Biol. Ther. 7(11), 1723-1730 (2007).
77. Acres B, Apostolopoulos V, Balloul JM et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol. Immunother. 48(10), 588-594 (2000).
78. Scholl SM, Balloul JM, Le Goc G et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. 23(5), 570-580 (2000).
79. Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med. 5(8), 690-699 (2003).
80. Pantuck AJ, van Ophoven A, Gitlitz BJ et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J. Immunother. 27(3), 240-253 (2004). • Use of vaccinia virus carrying MUC1 and IL-2 genes induces immune responses in patients with prostate cancer.
81. Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev. Vaccines 7(7), 889-893 (2008).
82. Madan RA, Arlen PM, Gulley JL. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin. Biol. Ther. 7(4), 543-554 (2007).
83. Kaufman HL, Kim-Schulze S, Manson K et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J. Transl. Med. 5, 60 (2007).
84. Gulley JL, Arlen PM, Tsang KY et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14(10), 3060-3069 (2008).
85. Hird V, Maraveyas A, Snook D et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer 68(2), 403-406 (1993).
86. Hughes OD, Bishop MC, Perkins AC et al. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J. Clin. Oncol. 18(2), 363-370 (2000).
87. Nicholson S, Bomphray CC, Thomas H et al. A Phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol. Immunother. 53(9), 809-816 (2004).
88. Vaughan HA, Ho DW, Karanikas V, Sandrin MS, McKenzie IF, Pietersz GA. The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan. Vaccine 18(28), 3297-3309 (2000).
89. Vaughan HA, Ho DW, Karanikas VA et al. Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates. Vaccine 17(20-21), 2740-2752 (1999).
90. Xing PX, Apostolopoulos V, Karkaloutsos J, McKenzie IF. Monoclonal antibodies to mucin VNTR peptides. Methods Mol. Biol. 125, 369-381 (2000).
91. Xing PX, Apostolopoulos V, Pietersz G, McKenzie IF. Anti-mucin monoclonal antibodies. Front. Biosci. 6, D1284-D1295 (2001).
92. Xing PX, Lees C, Lodding J et al. Mouse mucin 1 (MUC1) defined by monoclonal antibodies. Int. J. Cancer 76(6), 875-883 (1998).
93. Jerome KR, Kirk AD, Pecher G, Ferguson WW, Finn OJ. A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol. Immunother. 43(6), 355-360 (1997).
94. + T cells in mice. Gives evidence that autoimmunity can be induced when using self antigens for cancer immunotherapy studies.
95. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. 18(3), 574-583 (2000). • Demonstration that antibodies to MUC1 in patients with breast cancer enhances long-term survival.
96. Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol. 155(10), 4766-4774 (1995).
97. Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell. Immunol. 194(2), 143-149 (1999).
98. Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine 18(19), 2059-2071 (2000).
99. Sheng KC, Kalkanidis M, Pouniotis DS et al. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur. J. Immunol. 38(2), 424-436 (2008).
100. Sheng KC, Pouniotis DS, Wright MD et al. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 118(3), 372-383 (2006).
101. Slovin SF, Ragupathi G, Fernandez C et al. A polyvalent vaccine for high-risk prostate patients: 'are more antigens better?' Cancer Immunol. Immunother. 56(12), 1921-1930 (2007). • Multivalent vaccine comprising six to eight antigens for immunotherapy of prostate cancer. Do more antigens included in the vaccine improve the responses? Results are discussed in this paper.
102. Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit. Rev. Immunol. 27(5), 451-462 (2007).
103. Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 25(Suppl. 2), B89-B96 (2007).
104. Holmberg LA, Oparin DV, Gooley T, Sandmaier BM. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope). Clin. Breast Cancer 3(Suppl. 4), S144-S151 (2003).
105. Holmberg LA, Sandmaier BM. Theratope vaccine (STn-KLH). Expert Opin. Biol. Ther. 1(5), 881-891 (2001).
106. Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev. Vaccines 3(6), 655-663 (2004). • Nice review of the Theratope® (STn-KLH) vaccine.
107. Ibrahim NK, Murray JL. Clinical development of the STn-KLH vaccine (Theratope). Clin. Breast Cancer 3(Suppl. 4), S139-S143 (2003).
108. Miles D, Papazisis K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin. Breast Cancer 3(Suppl. 4), S134-S138 (2003).
109. Immunotherapy to fight cancer and infectious diseases www.transgene.fr